FKBP4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL611146	0.51	14/20
SCHEMBL611147	0.51	14/20
SCHEMBL609094	0.48	13/20
SCHEMBL609095	0.48	13/20
SCHEMBL610969	0.63	10/20
SCHEMBL610971	0.63	10/20
SCHEMBL416985	0.56	10/20
SCHEMBL416986	0.56	10/20
SCHEMBL420109	0.54	8/20
SCHEMBL420110	0.54	8/20
SCHEMBL3185117	0.54	8/20
SCHEMBL619873	1.00	7/20
SCHEMBL619874	1.00	7/20
SCHEMBL611145	0.80	7/20
SCHEMBL419423	0.79	7/20
SCHEMBL419424	0.79	7/20
SCHEMBL609093	0.77	7/20
SCHEMBL1107277	0.60	7/20
SCHEMBL418764	0.57	7/20
SCHEMBL418765	0.57	7/20

Clinical trials — most relevant to FKBP4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris	PHASE4	UNKNOWN
Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients	PHASE4	COMPLETED
Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities	PHASE3	COMPLETED
Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)	PHASE2	COMPLETED
Cyclosporine For The Treatment Of COVID-19(+)	PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Neurosteroids for PTSD in Veterans	PHASE2	COMPLETED
FK506 (Tacrolimus) in Pulmonary Arterial Hypertension	PHASE2	COMPLETED
A Multicenter Study of NAP (AL-108) in Schizophrenia	PHASE2	COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors	PHASE1	WITHDRAWN
Multimodal Neuroimaging of Alcohol Cues, Cortisol Response, and Compulsive Motivation	EARLY_PHASE1	COMPLETED
Cortisol, Hippocampus, and Insula in Anorexia Nervosa.	nan	RECRUITING
FKBP5 Methylation and Childhood Emotional Abuse in Complex Posttraumatic Stress Disorder: Investigating the Relationship and Its Predictive Role in Therapy Outcome	nan	COMPLETED
Clinical Implications of FKBP5 in Stroke	nan	UNKNOWN
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer	nan	WITHDRAWN
A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES)	nan	UNKNOWN
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
Genetic Predictors of Lithium Response in Bipolar Disorder	nan	COMPLETED
Sensorimotor Gating in Schizophrenia	nan	COMPLETED
Gene Polymorphisms in Tacrolimus Drug Interactions	nan	COMPLETED
Poor Sleep During Pregnancy as Risk Factor for Post-partum Stress and Mental Health	nan	RECRUITING
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based Dosing in a Multi-ethnic Population of Kidney Transplant Recipients in Singapore	nan	COMPLETED
The Partners Genetics Collaborative Study of Schizophrenia	nan	COMPLETED
Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FKBP4 binder may also engage these)

Protein	Name	Similarity
Q95L05	—	1.000	Q95L05 →
P27124	—	1.000	P27124 →
Q64378	—	1.000	Q64378 →
Q9TRY0	—	1.000	Q9TRY0 →
Q9QVC8	—	0.998	Q9QVC8 →
P30416	—	0.998	P30416 →
Q5U2T9	—	0.996	Q5U2T9 →
Q9XT11	—	0.995	Q9XT11 →
Q5RF88	—	0.994	Q5RF88 →
FKBP5	Peptidyl-prolyl cis-trans isomerase FKBP5	0.991	landscape →
Q9FJL3	—	0.991	Q9FJL3 →
Q43207	—	0.989	Q43207 →
Q9XSI2	—	0.989	Q9XSI2 →
Q9XSH5	—	0.987	Q9XSH5 →
Q9VL78	—	0.987	Q9VL78 →
Q5FWY5	—	0.983	Q5FWY5 →
Q38931	—	0.983	Q38931 →
Q95MN9	—	0.981	Q95MN9 →
Q6ES52	—	0.981	Q6ES52 →
Q9EQW7	—	0.980	Q9EQW7 →
Q6DGG0	—	0.980	Q6DGG0 →
Q07G10	—	0.980	Q07G10 →
Q8R0F9	—	0.980	Q8R0F9 →
P26882	—	0.980	P26882 →
FKBP3	Peptidyl-prolyl cis-trans isomerase FKBP3	0.979	landscape →
B5MCN3	—	0.979	B5MCN3 →
Q5D892	—	0.979	Q5D892 →
P28049	—	0.979	P28049 →
B3MYY4	—	0.979	B3MYY4 →
Q0VD48	—	0.979	Q0VD48 →